Precision Biosciences Inc stock is traded at $9.71, with a volume of 360,312. It is down -1.62% in the last 24 hours and up +56.61% over the past month. Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Previous Close:
$9.87
Open:
$9.80
24h Volume:
360,312
Relative Volume:
0.75
Market Cap:
$271.26M
Revenue:
$45.07M
Net Income/Loss:
-$44.49M
P/E Ratio:
-
EPS:
-$3.72
Net Cash Flow:
-$54.23M
1W Performance:
+37.54%
1M Performance:
+56.61%
6M Performance:
+29.12%
1Y Performance:
+50.78%
1-Day Range:
$9.07$9.98
1-Week Range:
$6.64$11.29
52-Week Range:
$3.53$11.29
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences IncSector
HealthcareIndustry
BiotechnologyPhone
919-314-5512Address
302 EAST PETTIGREW STREET, DURHAM, NC, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS